Results of Operations and Financial Condition. On August 6, 2026, Artiva Biotherapeutics, Inc. (“Artiva”) issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1. The information contained under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subje…

Director and CFO — Diego Miralles, M.D. and Thad Huston: Dr. Diego Miralles resigned as a Director to take on an internal promotion, and Thad Huston departed from his CFO role with severance.

Other Events. On May 8, 2026, Artiva Biotherapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC and Cantor Fitzgerald & Co., as representatives of the several underwriters listed therein (collectively, the “Underwriters”), to issue and sell 23,871,526 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) at a price of $11.52 per share and pre-funded warr…

Results of Operations and Financial Condition. On May 8, 2026, Artiva Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1. The information contained under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise su…

Other Events. ATM Suspension On May 8, 2026, the Company delivered written notice to Leerink Partners LLC (“Leerink”) that the Company has suspended and is not offering any shares of its common stock pursuant to the prospectus filed with the SEC on August 6, 2025, relating to the Sales Agreement, dated August 6, 2025 (the “Sales Agreement”), by and between the Company and Leerink. The Company will not make any sales of common stock pursuant to the Sales Agreement unless and until a new prospe…

Results of Operations and Financial Condition. On March 10, 2026, Artiva Biotherapeutics, Inc. (“Artiva”) issued a press release announcing its financial results for the year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information contained under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subj…

Chief Financial Officer — Thad Huston: Artiva Biotherapeutics appointed Thad Huston as the new Chief Financial Officer.

Director — Elaine Sorg: Elaine Sorg was appointed as a Class I director of Artiva Biotherapeutics, Inc.

The company implemented an exchange program to replace underwater stock options with RSUs for certain employees.

Results of Operations and Financial Condition. On November 12, 2025, Artiva Biotherapeutics, Inc. (“Artiva”) issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information contained under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwi…

Other Events. Initial Safety and Tolerability Data AlloNK is currently being explored in three ongoing Phase 1 and 2 clinical trials for the treatment of refractory rheumatoid arthritis (RA), Sjögren’s disease (SjD), idiopathic inflammatory myopathies, systemic sclerosis (SSc), and systemic lupus erythematosus (SLE)/lupus nephritis (LN). All patients receive a standard conditioning regimen of cyclophosphamide (Cy) and fludarabine (Flu) prior to treatment with AlloNK (three weekly doses) and a…

Results of Operations and Financial Condition. On August 6, 2025, Artiva Biotherapeutics, Inc. (“Artiva”) issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information contained under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subje…

The filing is about an equity plan amendment, not a management change.

Results of Operations and Financial Condition. On May 8, 2025, Artiva Biotherapeutics, Inc. (“Artiva”) issued a press release announcing its financial results for the quarter ended March 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information contained under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject…

Results of Operations and Financial Condition. On March 24, 2025, Artiva Biotherapeutics, Inc. (“Artiva”) issued a press release announcing its financial results for the year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1. The information contained under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subj…

Class I director and member of the Clinical Strategy Committee — Daniel Baker, Ph.D.: Dr. Daniel Baker was appointed as a Class I director and member of the Clinical Strategy Committee.

Results of Operations and Financial Condition. On November 12, 2024, Artiva Biotherapeutics, Inc. (“Artiva”) issued a press release announcing its financial results for the quarter ended September 30, 2024. A copy of the press release is attached hereto as Exhibit 99.1. The information contained under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwi…

Director — Alison Moore, Ph.D.: Dr. Alison Moore was appointed as a Class III director and member of the Technical Operations Committee.

Results of Operations and Financial Condition. On August 29, 2024, Artiva Biotherapeutics, Inc. (“Artiva”) issued a press release announcing its financial results for the quarter ended June 30, 2024. A copy of the press release is attached hereto as Exhibit 99.1. The information contained under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subj…